Targeted delivery of RNAi therapeutics for cancer therapy

Nanomedicine

Volumn 5, Issue 10, 2010, Pages 1483-1486

  Li, Jun ^a   Huang, Leaf ^a  

^a University of North Carolina   (United States)

Author keywords

SiRNA

Indexed keywords

DOXORUBICIN; MACROGOL; SMALL INTERFERING RNA;

CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EDITORIAL; ENDOCYTOSIS; ENDOSOME; MICELLE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; RNA INTERFERENCE; TUMOR CELL;

ANIMALS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 78650564093     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.124     Document Type: Editorial

References (33)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998). (Pubitemid 28099681)
2. Zamore PD, Tuschl T, Sharp PA, Bartel DP: RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25-339 (2000).
3. Whitehead KA, Langer R, Anderson DG: Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129-138 (2009).
4. Harris JM, Chess RB: Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214-221 (2003).
5. Xu Y, Szoka FC Jr: Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35, 5616-5623 (1996). (Pubitemid 26143656)
6. Hafez IM, Maurer N, Cullis PR: On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8, 1188-1196 (2001). (Pubitemid 32776393)
7. Semple SC, Akinc A, Chen J et al.: Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172-176 (2010).
8. Akinc A, Querbes W, De S et al.: Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357-1364 (2010).
9. Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLachlan I: A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm. Res. 22, 362-372 (2005). (Pubitemid 40558494)
10. Zimmermann TS, Lee AC, Akinc A et al.: RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114 (2006). (Pubitemid 43827961)
11. Akinc A, Zumbuehl A, Goldberg M et al.: A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561-569 (2008). (Pubitemid 351668042)
12. Akinc A, Goldberg M, Qin J et al.: Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther 17, 872-879 (2009).
13. Love KT, Mahon KP, Levins CG et al.: Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864-1869 (2010).
14. Judge AD, Robbins M, Tavakoli I et al.: Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119, 661-673 (2009).
15. Li S, Huang L. In vivo gene transfer via intravenous administration of cationic lipid- protamine-DNA (LPD) complexes. Gene Ther. 4, 891-900 (1997). (Pubitemid 27437714)
16. Li S, Rizzo MA, Bhattacharya S, Huang L: Characterization of cationic lipid-protamine- DNA (LPD) complexes for intravenous gene delivery. Gene Ther. 5, 930-937 (1998). (Pubitemid 28371910)
17. Li SD, Chen YC, Hackett MJ, Huang L: Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther. 16, 163-169 (2008).
18. Li SD, Huang L: Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta 1788, 2259-2266 (2009).
19. Li SD, Chono S, Huang L: Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 16, 942-946 (2008). (Pubitemid 351587105)
20. Chono S, Li SD, Conwell CC, Huang L: An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J. Control. Release 131, 64-69 (2008).
21. Li J, Chen YC, Tseng YC, Mozumdar S, Huang L: Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J. Control. Release 142, 416-421 (2010).
22. Landen CN, Jr, Chavez-Reyes A, Bucana C et al.: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918 (2005). (Pubitemid 41060730)
23. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG: PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 116, 123-129 (2006).
24. Han HD, Mangala LS, Lee JW et al.: Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res. 16, 3910-3922 (2010).
25. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ: Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewings sarcoma. Cancer Res. 65, 8984-8992 (2005). (Pubitemid 41377390)
26. Davis ME, Zuckerman JE, Choi CH et al.: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
27. Rozema DB, Lewis DL, Wakefield DH et al.: Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104, 12982-12987 (2007). (Pubitemid 351737577)
28. Musacchio T, Vaze O, DSouza G, Torchilin VP: Effective stabilization and delivery of siRNA: reversible siRNA- phospholipid conjugate in nanosized mixed polymeric micelles. Bioconjug. Chem. 21, 1530-1536 (2010).
29. Song E, Zhu P, Lee SK et al.: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717 (2005). (Pubitemid 41716361)
30. Takeshita F, Minakuchi Y, Nagahara S et al.: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl Acad. Sci. USA 102, 12177-12182 (2005). (Pubitemid 41291148)
31. Yan W, Chen W, Huang L: Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J. Control. Release 130, 22-28 (2008).
32. Fedorov Y, Anderson EM, Birmingham A et al.: Off-target effects by siRNA can induce toxic phenotype. RNA 12, 1188-1196 (2006). (Pubitemid 43990544)
33. Jackson AL, Burchard J, Leake D et al.: Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12, 1197-1205 (2006) (Pubitemid 43990545)